Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences

Benzer Materyaller

• Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4
  Yazar:: Rudwaleit, M., ve diğerleri
  Baskı/Yayın Bilgisi: (2000)
• Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept
  Yazar:: Zou, J, ve diğerleri
  Baskı/Yayın Bilgisi: (2003)
• Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab
  Yazar:: Baraliakos, X, ve diğerleri
  Baskı/Yayın Bilgisi: (2005)
• Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis
  Yazar:: Rudwaleit, M, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)
• Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
  Yazar:: Listing, J, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)